

#

**Study #NNMC-59: A Randomized Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjuvant Radiation**

NAV1.954721.001

**Location:** NNMC, Bethesda

**Date:** December, 1993 - Present

**Primary**

**Researchers:** CAPT J. D. Nash, MC USN, Dr. Rolland J. Barrett, M. D., Dr. Richard Stock, M. D., Dr. Frederick Stehman, M. D., Dr. Gillian Thomas, M. D., Dr. Robert C. Park, M. D., Dr. John Blessing, Ph. D., Dr. J. Tate Thigpen, M. D. and Dr. William Hoskins, M. D.

**Sponsors:** Clinical Investigation Program, NNMC

**Human**

**Subjects:** Numbers unknown. Patients must have primary, histologically confirmed invasive squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the uterine cervix. clinical Stages I-A2, I-B or II-A. Informed consent obtained in writing.

**Purpose: Protocol: B94-018**

1. To determine whether the combination of 5-fluorouracil (f-FU) and cisplatin used as an adjunct to radiation therapy will improve survival rate of progression-free survival and decrease extra pelvic failure compared to radiation therapy alone in patients iwth positive pelvic lymph nodes, positive parametrial involvement or positive surgical margins following radical hysterectomy and lymph node dissection for Stages I-A2, I'B and II-A carcinoma of the cervix.
2. To determine the increase in toxicities due to 5-FU and cisplatin as an adjunct to radiation therapy versus radiation therapy alone.

**Category:** Treatment use of Radiation

**Records:** NNMC, Bethesda

**Classification:** Unclassified

CIP- NNMC- ENCL (25)